127120 - JS Link

127120 Summary

Biopharma

Stock Price & Overview

₩33,600 +3,700 (+12.37%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩33,600 ≈ US$24 · Market cap ₩1.2tn (≈ $879m)

127120 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	19.3	15.9	21.9	17.0	23.0	15.3	15.6	14.9	14.5	11.5	9.4
Cost of Revenue	15.7	13.1	16.4	13.8	16.7	13.0	12.6	11.0	8.2	11.1	11.6
Gross Profit	3.6	2.8	5.5	3.2	6.3	2.3	3.0	3.9	6.2	0.4	-2.2
Selling, General & Administrative	16.1	11.9	9.9	8.3	11.5	10.4	8.8	6.8	5.3	6.8	5.7
Operating Income	-12.5	-9.1	-4.3	-5.1	-5.2	-8.1	-5.8	-2.9	0.9	-6.3	-8.0
Finance Income	1.1	2.2	0.7	0.9	0.3	1.0	0.7	1.5	0.0	0.2	0.1
Finance Costs	3.8	0.8	0.3	0.4	0.3	5.5	2.9	0.9	1.3	1.5	1.0
Pretax Income	-16.4	-10.8	-5.6	-8.1	-6.2	-13.8	-13.1	-3.8	0.3	-9.9	-9.1
Income Tax Expense	—	—	—	0.0	0.0	0.0	-0.0	—	-0.0	-0.1	-0.0
Net Income	-16.4	-10.8	-5.6	-8.1	-6.2	-13.8	-13.1	-3.8	0.3	-9.8	-9.1
Total Comprehensive Income	-16.2	-11.3	-6.6	-7.3	-7.1	-13.9	-13.1	-4.1	0.9	-9.6	-9.3

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	123.0	54.4	38.8	43.5	41.0	52.5	25.9	35.1	25.1	25.9	32.7
Current Assets	55.0	14.3	14.5	18.7	33.4	47.4	14.6	22.5	15.1	13.4	15.4
Cash & Cash Equivalents	40.4	4.7	6.6	10.7	5.9	36.9	6.4	11.8	5.0	3.0	6.0
Inventories	4.9	2.6	3.8	2.9	1.9	3.8	3.8	2.3	1.9	2.8	2.4
Trade Receivables	6.7	3.6	3.0	3.9	6.9	3.7	3.9	6.1	4.8	2.2	2.3
Non-current Assets	68.0	40.1	24.3	24.8	7.6	5.1	11.3	12.5	9.9	12.4	17.4
Property, Plant & Equipment	57.9	22.7	7.3	7.0	5.8	3.2	4.9	4.3	3.2	4.7	7.3
Intangible Assets	0.2	0.2	0.2	0.3	0.2	0.2	1.9	3.1	2.9	1.9	1.5
Total Liabilities	54.4	29.4	12.5	15.6	10.7	15.1	16.2	15.5	1.4	24.0	21.5
Current Liabilities	48.1	27.1	8.9	10.5	9.3	14.6	15.5	14.5	1.3	3.7	2.7
Non-current Liabilities	6.4	2.2	3.6	5.1	1.3	0.5	0.7	0.9	0.2	20.3	18.8
Total Equity	68.6	25.0	26.3	27.9	30.4	37.5	9.7	19.6	23.7	1.8	11.2
Share Capital	16.0	11.2	9.3	8.5	8.2	8.2	5.7	5.4	5.4	3.1	3.1
Retained Earnings	-102.6	-86.3	-75.0	-68.9	-61.8	-56.0	-42.8	-29.7	-25.6	-26.1	-16.6

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	-9.4	-6.8	-5.0	0.9	-6.4	0.8	-1.3	-1.6	-2.5	-3.8	-3.7
Cash from Investing Activities	-33.4	-18.6	-3.7	-2.7	-23.1	1.6	-4.2	-3.5	6.2	-0.8	-13.1
Purchase of Property, Plant & Equipment	44.0	16.7	2.9	4.9	4.0	1.1	2.6	2.5	0.8	1.3	3.5
Cash from Financing Activities	78.4	23.5	4.6	6.6	-1.7	28.2	0.0	11.9	-1.6	1.6	20.9
Net Change in Cash	35.6	-1.9	-4.2	4.9	-31.2	30.6	-5.4	6.8	2.1	-3.0	4.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	6.3	2.4	8.9	5.2	3.8	1.4	5.7	4.1	3.1	3.1
Cost of Revenue	3.6	2.8	5.8	4.8	2.6	2.5	4.1	3.4	2.5	3.2
Gross Profit	2.7	-0.4	3.1	0.3	1.3	-1.1	1.6	0.7	0.6	-0.1
Selling, General & Administrative	6.9	4.5	4.6	4.2	3.6	3.8	3.3	3.2	3.0	2.4
Operating Income	-4.2	-4.9	-1.4	-3.9	-2.4	-4.8	-1.7	-2.5	-2.4	-2.5
Finance Income	13.8	0.1	0.7	0.1	0.2	0.1	1.9	0.2	0.1	0.1
Finance Costs	1.1	1.0	2.7	0.3	0.5	0.1	0.5	0.1	0.2	0.1
Pretax Income	8.0	-3.8	-5.7	-3.8	-2.5	-4.5	-1.7	-6.0	-3.0	-0.1
Income Tax Expense	—	—	—	—	—	—	—	—	0.0	0.0
Net Income	8.0	-3.8	-5.7	-3.8	-2.5	-4.5	-1.7	-6.0	-3.0	-0.1
Total Comprehensive Income	8.2	-3.6	-5.4	-3.8	-2.5	-4.5	-2.1	-6.1	-2.7	-0.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	187.7	143.3	123.0	94.7	75.1	60.4	54.4	50.9	40.9	40.5
Current Assets	114.9	74.7	55.0	27.2	18.7	13.0	14.3	23.5	12.6	12.1
Cash & Cash Equivalents	72.2	59.0	40.4	14.0	8.0	4.4	4.7	9.6	2.9	4.4
Inventories	9.8	5.7	4.9	4.4	4.5	2.7	2.6	3.7	4.0	3.2
Trade Receivables	8.0	4.5	6.7	3.6	3.6	3.6	3.6	3.8	3.1	3.8
Non-current Assets	72.8	68.6	68.0	67.5	56.4	47.3	40.1	27.4	28.3	28.4
Property, Plant & Equipment	63.1	58.7	57.9	52.6	41.4	39.2	22.7	8.9	7.2	8.2
Intangible Assets	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Total Liabilities	84.2	54.0	54.4	48.6	36.2	29.8	29.4	24.6	17.3	14.6
Current Liabilities	74.0	43.5	48.1	46.7	34.3	27.3	27.1	20.6	13.7	11.1
Non-current Liabilities	10.2	10.4	6.4	1.9	1.9	2.5	2.2	4.0	3.6	3.5
Total Equity	103.5	89.4	68.6	46.1	38.9	30.5	25.0	26.4	23.6	25.9
Share Capital	17.4	17.2	16.0	15.0	13.5	12.2	11.2	11.2	9.3	9.3
Retained Earnings	-97.1	-106.4	-102.6	-97.1	-93.2	-90.8	-86.3	-84.1	-78.1	-75.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-7.0	-5.4	-3.2	-2.0	-1.0	-3.1	3.5	-6.2	-1.7	-2.3
Cash from Investing Activities	-9.0	-1.8	-2.4	-16.1	-7.3	-7.7	-13.2	-2.2	-1.4	-1.8
Purchase of Property, Plant & Equipment	6.4	2.0	5.9	13.3	8.1	16.7	17.5	-1.0	0.2	0.1
Cash from Financing Activities	29.8	23.8	32.0	23.9	12.1	10.4	4.9	15.1	1.6	1.9
Net Change in Cash	13.8	16.6	26.4	5.8	3.8	-0.4	-4.8	6.7	-1.5	-2.2

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

127120 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	19.3	+21.4%	+4.4%	+4.8%	+7.4%
Operating income	-12.5	—	—	—	—
Net income	-16.4	—	—	—	—
EPS	₩-449	—	—	—	—
Operating cash flow	-9.4	—	—	—	—
Shareholders' equity	68.6	+174.0%	+35.0%	+12.8%	+19.9%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

127120 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	18.9%	17.7%	25.2%	18.6%	27.4%	15.2%
Operating margin	-64.6%	-57.3%	-19.8%	-30.3%	-22.4%	-52.7%
Net margin	-85.1%	-67.9%	-25.5%	-47.6%	-26.9%	-90.1%
Return on equity	-35.1%	-42.1%	-20.7%	-27.7%	-18.3%	-58.4%
Return on assets	-18.5%	-23.2%	-13.6%	-19.1%	-13.2%	-35.1%
Operating cash flow / revenue	-48.6%	-42.6%	-22.9%	5.4%	-28.0%	5.6%
Capex / revenue	228.0%	105.1%	13.1%	29.0%	17.5%	7.2%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 127120

Symbol	Last Price
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%
069620Daewoong Pharma	₩116,100 +1.1%
290650L & C BIO Co., Ltd.	₩47,900 -1.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%
003090Daewoong Co., Ltd.	₩16,860 -2.0%
086450Dong Kook Pharmaceutical Co., Ltd.	₩21,600 -0.9%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.